Assembly Biosciences (ASMB) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 19.5% versus a loss of 3.8%. Over five years, ASMB leads with a -41.3% price change compared with -93.2% for CBIO. Crescent Biopharma is the larger company by market cap ($496.7 million vs $449.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | CBIO |
|---|---|---|
| Share price | $22.08 | $13.37 |
| Market cap | $449.56M | $496.65M |
| 1-day change | -3.79% | -0.89% |
| YTD return | -32.52% | +13.74% |
| 1-year return | -3.81% | +19.49% |
| 5-year return | -41.33% | -93.19% |
| P/E ratio (TTM) | 21.23 | — |
| EPS (TTM) | $1.04 | $-7.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $27.41 |
| 52-week low | $21.80 | $8.72 |
| Distance from 52-week high | -44.40% | -51.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +135.51% | +135.60% |
| Average volume | 278.07K | 397.58K |
| Shares outstanding | 20.36M | 37.14M |
| Employees | 73 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed ASMB by 23.3 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ASMB vs CBIO FAQ
Which is bigger, Assembly Biosciences or Crescent Biopharma?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $496.65M compared with $449.56M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or CBIO?
CBIO returned +19.49% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.